



DEVELOPMENT AND EVALUATION OF TOPICAL LIPOSOMAL GEL LOADED WITH TAZAROTENE IN COMBINATION WITH HYDROQUINONE

A. Bhardwaj, M.L. Kori*

Vedica college of B. Pharmacy, R.K.D.F. University, Gandhi Nagar Bhopal (M.P.)

*Corresponding Author's E mail: mohanlalkori@gmail.com

Received 22 Mar. 2018; Revised 28 Mar. 2018; Accepted 30 Mar. 2018, Available online 15 Apr. 2018

ABSTRACT

The aim of the present study was to statistically optimize the vesicular formulations (Liposomes) for enhanced skin delivery of a model drug tazarotene in combination with gel contains hydroquinone. Regular 2³ factorial designs were employed for screening of significant formulation and process variables involved in the development of liposome. The optimization batches (TL1 to TL8) were prepared by lipid film hydration method with different concentration of lecithin and cholesterol with different varying stirring speed (100 and 200 rpm) All the prepared formulation were characterized for vesicle morphology, particle size and entrapment efficiency by transmission electron microscopy (TEM). The optimized batch of tazarotene liposome TL6 was further incorporated into gel containing hydroquinone. Three different formulation (LF1, LF2, LF3) were prepared using different composition of carbopol (0.5, 1.0 and 2%) The optimized batch of tazarotene and hydroquinone incorporated gel (1%) was characterized for pH, spreadability, viscosity (cps) and *in vitro* drug release. The percentage drug entrapment efficiency found higher in formulation TL6, Vesicular size and drug entrapment efficiency of the optimized liposomes were found to be 180.4 nm and 69.10% respectively. *In-vitro* diffusion study demonstrated that the drug diffused from liposomal gel and conventional marketed gel was found to be 98.12% and 98.58% respectively. It can be concluded from the experimental results that the liposomal gel containing tazarotene in combination with hydroquinone has potential application in topical delivery.

Keywords: Tazarotene, Hydroquinone, Liposome, Gel, Topical Drug Delivery.

INTRODUCTION

Liposome technology is one of the fastest growing scientific fields contributing to areas such as drug delivery, cosmetics, nanotechnology etc. This is due to several advantageous characteristics of liposomes such as ability to incorporate not only water soluble but also lipid soluble agents, specific targeting to the required site in the body and versatility in terms of fluidity, size, charge and number of lamellae¹. The first report indicating that topical application of liposomally encapsulated drugs altered drug deposition was presented at the FIP 1979 congress. Mezei and Gulasekharan initiated research for utilizing liposomes as drug carriers for topical delivery in the early 1980s. With continuous efforts researchers succeeded in commercializing the liposomal gel for topical delivery of econazole in 1988 by Pevaryl T. M, Cilag, Switzerland. Mezei and Gulasekharan reported that topical application of liposomal triamcinolone acetonide for 5 days resulted in a drug concentration in the epidermis and dermis four

times higher than that obtained using a control ointment, while urinary excretion of the drug was diminished. Therefore, their results indicated that the use of liposomes might be useful for increased local activity while diminishing the percutaneous absorption of the drug².

Depending upon their solubility and partitioning characteristics, the drug molecules are located differently in the liposomal environment and exhibit different entrapment and release properties. Highly hydrophilic drugs with $\log P \leq 0.3$, are located exclusively in the aqueous compartments of the liposomes. Highly lipophilic drugs, with $\log Poct \geq 5$, are entrapped almost completely in the lipid bilayer of the liposomes, drugs with intermediate partition coefficients, i.e., $1.7 \leq \log Poct \leq 4$, pose a major problem because they partition easily between the lipid and aqueous phases and are very easily lost from the liposomes. Such molecules form stable liposomal systems only when they form complexes with the membrane lipids³. However, the most problematic candidates for liposomal entrapment are the drug molecules which have poor biphasic solubility (e.g. mercaptopurine, azathioprine and allopurinol).

Liposomes are thought to act as “drug localizers” - not only as “drug transporters”⁴. This is the reason why this study focuses on liposomes as a promising form for topical drug delivery. Although most topical liposome studies have focused on drug deposition into the stratum corneum, a growing number of studies have yielded evidence of follicular delivery via liposomes⁵. Therefore, the present study was aimed to statistically optimize the vesicular formulations (Liposomes) for enhanced skin delivery of a model drug tazarotene in combination with gel contains hydroquinone.

MATERIALS AND METHODS

Tazarotene and hydroquinone was gift sample from Bioplus life science, Bangalore, India. Soya lecithin was purchased from Hi Media Ltd. Mumbai. Cholesterol was purchased from Thomas baker, methanol, chloroform, propylene glycol, was purchased from S. D. Fine Chem. Ltd., Mumbai. Ethanol was procured from Qualigens fine chemicals, Mumbai. All other chemicals were of analytical grade and double distilled water used throughout the experiment.

Optimization of formulation

Regular 2³ factorial designs were employed for screening of significant formulation and process variables involved in the development of Liposome. Table 1 presents the description of high and low levels of various variables screened for their influence in the development of liposome of tazarotene. Table 1 depicts the L8 array for the three factors, two levels design adopted in the current studies. When the data of table 1 put into the DoE, it will provide combinations of 8 formulations as listed in table 1 as TL1 to

TL8. Particle size and entrapment efficiency were the key response variables investigated thoroughly for selecting the significant formulation and response variables⁶.

Method of preparation for Liposomes

Liposomes were prepared by lipid film hydration method using rotary vacuum evaporator. Drug Tazarotene (constant), SPC: CHOL: rotation speed ratio was altered and vesicle size and drug entrapment efficiency were studied. Briefly, a chloroform: methanol (1:2) mixture of different ratio of drug Tazarotene (constant), SPC: CHOL: rotation speed evaporator under vacuum at $40 \pm 0.5^{\circ}$ C to form a lipid film on the wall of a round bottom flask. The resulting lipid film was then hydrated with phosphate buffer (pH 7.4) for 2 hours at $37 \pm 0.5^{\circ}$ C. The preparation was sonicated at 4° C in 3 cycles of the 5 minutes and rest of 5 minutes between each cycle by using probe sonicator. The formulation was homogenized at 15,000 psi pressure in 3 cycles using high-pressure homogenizer to get liposome⁷.

Evaluation of liposome

Vesicle size determination

Vesicle size were determined using the particle size analyzer (Horiba nanoparticle analyzer, SZ-100-S, Kyoto, Japan)

Entrapment efficiency

Tazarotene was estimated in liposome by ultra-centrifugation method liposomal suspension was transferred to 10 ml centrifuge tube. This suspension was diluted with distilled water up to 5 ml and centrifuged at 2000 rpm for 20 minutes. By this we can separate undissolved drug in the formulation. Suitable volume of the protamine solution was added to the resulting supernatant and retained for 10 minutes. Liposomes were aggregated in presence of protamine and then separated by ultra centrifugation at 15,000 rpm for 20 minutes. Supernatant and sediment were separated out. Volumes of the supernatant and sediment were measured. Sediment was diluted with distilled water up to 5 ml. The untrapped and entrapped drug contents were analyzed by estimating drug in supernatant and liposomes (sediment) by spectroscopic method⁸.

Transmission electron microscopy

Image of the internal structure was determined by TEM, for TEM a drop of the sample was placed on a carbon-coated copper grid and after 15 minutes it was negatively stained with 1% aqueous solution of

phosphotungstic acid. The grid was allowed to air dry thoroughly and samples were viewed on a transmission electron microscopy (TEM Hitachi, H-7500 Tokyo, Japan)⁹.

Preparation of gels

Preparation of carbopol gel base

0.5 g Carbopol 934 was weighed and dispersed in distilled water with mild stirring and allowed to swell for 24 hours to obtain 0.5% gel. Later 2 ml of glycerin was added to for gel consistency. Preservatives also added to it. Similarly 1 and 2% carbopol gels were prepared^{10, 11}.

Preparation of liposomal gels

1g of liposome formulation was dissolved in 10ml of ethanol and centrifuged at 6000 rpm for 20 minutes to remove the untrapped drug. The supernatant was decanted and sediment was incorporated into the gel vehicle¹². The incorporation of the tazarotene loaded liposomes (equivalent to 0.1%) and direct incorporation of hydroquinone (4%) into gels was achieved by slow mechanical mixing at 25 rpm (REMI type BS stirrer) for 10 minutes. The optimized formulation was incorporated into three different gel concentration 0.5, 1 and 2% w/w.

Evaluation of gels

Determination of pH

Weighed 50 gm of each gel formulation were transferred in 10 ml of beaker and measured it by using the digital pH meter. pH of the topical gel formulation should be between 3–9 to treat the skin infections¹³.

Spreadability

A modified apparatus suggested was used for determining spreadability. The spreadability was measured on the basis of slip and drag characteristics of the gels. The modified apparatus was fabricated and consisted of two glass slides, the upper one was fixed to a wooden plate and the lower one was attached by a hook to a balance. The spreadability was determined by using the formula: $S = ml/t$, where S, is spread ability, m is weight in the pan tied to lower slide and t is the time taken to travel a specific distance and l is the distance traveled. For the practical purpose the mass, length was kept constant and 't' was determined. The measurement of spreadability of each formulation was in triplicate and the average values are presented.

Measurement of viscosity

The viscosity of gels was determined by using a Brook Field viscometer DV-II model. A T-Bar spindle in combination with a helipath stand was used to measure the viscosity and have accurate readings.

Selection of spindle

The goal was to obtain a viscometer dial or display (% torque) reading between 10 and 100, the relative error of measurement improves as the reading approaches 100. Spindle T 95 was used for the measurement of viscosity of all the gels.

Spindle immersion

The T –bar spindle (T95) was lowered perpendicularly in the centre taking care that spindle does not touch bottom of the jar.

Measurement of viscosity

The T-bar spindle (T95) was used for determining the viscosity of the gels. The factors like temperature, pressure and sample size etc. which affect the viscosity were maintained during the process. The helipath T- bar spindle was moved up and down giving viscosities at number of points along the path. The torque reading was always greater than 10%. Five readings taken over a period of 60 sec. were averaged to obtain the viscosity.

Preparation of analysis of drugs

Gel equivalent to 10 mg of tazarotene and 10 mg of hydroquinone was weighed and transferred to a separate 10 ml volumetric flask and volume was made up to 10 ml with phosphate buffer to obtain concentration of 1000µg/ml. Resultant solution was filtered through Whatmann filter paper. 1 ml of filtrate was taken in 10 ml volumetric flask and volume was made up to 10 ml with same buffer to obtain concentration of 100µg/ml. Further 1 ml of this solution was taken and diluted up to 10 ml obtain final concentration of 10µg/ml. Absorbance of the sample solutions at 351.0 nm and 288.0 nm was measured and from the absorbance values, the concentration of drugs in the sample solution was determined by using Vierodt's formula. The contents were calculated using the following equations,

$$C_X = (A_2 a_{y1} - A_1 a_{y2}) / (a_{x2} a_{y1} - a_{x1} a_{y2})$$

$$C_Y = (A_1 a_{x2} - A_2 a_{x1}) / (a_{x2} a_{y1} - a_{x1} a_{y2})$$

where C_X and C_Y are the concentrations of tazarotene and hydroquinone respectively, ax_1 and ax_2 are the absorptivity values of tazarotene at 351 nm and at 288 nm respectively, ay_1 and ay_2 are the absorptivity values of hydroquinone at 288 nm and at 351 nm respectively and A_1 and A_2 are the absorbances of the diluted sample at 351 nm and at 288 nm respectively.

Absorptivity of tazarotene at 351.0 nm

Absorptivity of tazarotene at 288.0 nm

Absorptivity of hydroquinone at 351.0 nm

Absorptivity of hydroquinone at 288.0 nm

Set of two simultaneous equations for simultaneous estimation tazarotene and hydroquinone Where,

A_1 = Absorbance of sample solution at 351.0 nm

A_2 = Absorbance of sample solution at 288.0 nm

C_X = Concentration of tazarotene n in g/liter in sample solution

C_Y = Concentration of hydroquinone in g/liter in sample solution

After obtaining the recorded absorbances, A_1 and A_2 and substituting the values concentration of each drug can be calculated.

***In-vitro* diffusion study**

An *in-vitro* drug release study was performed using modified Franz diffusion cell. Dialysis membrane (Hi Media, Molecular weight 5000 Daltons) was placed between receptor and donor compartments. liposomal gel equivalent to 1 mg of Tazarotene was placed in the donor compartment and the receptor compartment was filled with phosphate buffer, pH 7.4 (24 ml). The diffusion cells were maintained at 37 ± 0.5 °C with stirring at 50 rpm throughout the experiment. At different time interval, 5 ml of aliquots were withdrawn from receiver compartment through side tube and analyzed for drug content by UV Visible spectrophotometer^{14, 15}.

Stability studies

Optimized formulations of tazarotene and hydroquinone loaded liposomes gel was subjected to accelerated stability testing under storage condition at 4 ± 1 °C and at room temperature 25 ± 1 °C. Both formulations were stored in screw capped, amber colored small glass bottles at 4 ± 1 °C and 25 ± 1 °C.

Analysis of the samples were characterized for vesicle size and drug content after a period of 7, 14, 21 and 28 days.

Effect of storage temperature on vesicle size

Subsequent change in vesicle size of the formulations stored at $4\pm 1^\circ\text{C}$ and $25 \pm 1^\circ\text{C}$ was determined using a Zetasizer (Malvern Instrument, UK) after a period of 7, 14, 21 and 28 days.

Effect of storage temperature on drug content

After storage for a specified period of time of 7, 14, 21 and 28 days, the drug content of both the formulations was determined. Drug content in liposomes gel was determined spectrophotometrically to indirectly estimate the amount of drug entrapped in liposomes gel.

RESULTS AND DISCUSSION

Preparation of liposomes was based on Taguchi design and was found to be well suited and sound approach to obtain stable liposome formulation for anti-bacterial drugs. Variables such as amount of phospholipid, amount of stabilizer have a profound effect on the vesicle size and entrapment efficiency.

Drug encapsulated liposome was prepared by hot method technique and lipid film hydration technique. Vesicular carriers were characterized for drug entrapment efficiency, vesicle size, and *in-vitro* diffusion study. Vesicular size and drug entrapment efficiency of the optimized liposomes were found to be 180.4 nm and 69.10% respectively. *In-vitro* diffusion study demonstrated that the drug diffused from liposomal gel and conventional marketed gel was found to be 98.12%, in 12 hrs.98.58% in 30 min. respectively.

Cholesterol may be included to improve bilayer characteristics of liposomes, increasing the microviscosity of the bilayers which in turn reduces the permeability of the membrane to water soluble molecules. This also results in the stabilization of the membrane and increase in the rigidity of the vesicles.

In the penetration enhancing mechanism, after application of vesicles, changes in the ultra structures of the intercellular lipids were seen suggesting a penetration enhancing effect. In vesicle adsorption to and/or fusion with the stratum corneum the vesicles may adsorb to the stratum corneum surface with subsequent transfer of drug directly from vesicles to skin or vesicles may fuse and mix with the stratum corneum lipid matrix, increasing drug partitioning into the skin. Liposomes have been reported to invade the skin intact and go deep enough to be absorbed by the systemic circulation.

Stability studies performed for optimized liposomal gel formulations indicate that prepared gel formulations have more stability at freezing temperature than at room temperature. Therefore, product should be stored at low temperatures (2-8 °C). The prepared liposomal gel formulations exhibit superior stability thereby increasing its potential application in transdermal delivery systems.

Table: 1 Composition of liposome on the basis of regular 2³ design

Run	B. No	Lecithin (mg)	Cholestrol (mg)	Stirring Speed (rpm)
1	TL1	100	20	200
2	TL2	100	50	200
3	TL3	200	20	100
4	TL4	200	20	200
5	TL5	200	50	200
6	TL6	100	20	100
7	TL7	100	50	100
8	TL8	200	50	100

Table: 2 Evaluations of liposomal formulations of regular 2³ designs

Formulation	Vesicle size (nm)	Zeta Potential (mv)	Entrapment efficiency (%)
TL1	165.3	-32.1	56.73±0.73
TL2	256.7	25.9	55.43±1.48
TL3	478.3	26.5	60.11±0.82
TL4	405.1	18.7	62.52±2.21
TL5	552.8	-32.8	64.87±1.54
TL6	180.4	-37.5	69.10±1.52
TL7	319.3	29.2	66.27±2.00
TL8	800.2	30.4	65.79±1.12




Fig. 1: Results of zeta potential




Fig. 2: Results of particle size

Table 3: Composition of optimized formulation of liposomes

Formulation Code	Lecithin (mg)	Cholesterol (mg)	Steering Speed (rpm)
TL6	100	20	100




Fig. 3: TEM image of optimized formulation of liposome

Table 4: Results of evaluation of liposomal gel formulations

Code	Drug content (%)		pH	Spreadability (Gm.cm/sec.)	Viscosity (cps)
	Tazarotene	Hydroquinone			
LF1	95.25±2.24	98.25±3.24	7.2±0.024	10.45±0.075	1870±25
LF2	98.15±1.28	99.15±2.28	7.0±0.035	12.32±0.042	1895±33
LF3	97.75±2.12	98.75±2.46	7.1±0.045	11.75±0.049	1875±21

*Average of 03 readings

Drug content from liposomal gel was found to follow the order LF2>LF3> LF1. In drug release study it was observed that the maximum drug release rate was shown in case of LF2 liposomal gel formulation. On the basis of results LF2 was selected as optimized gel formulation based in the drug release and other attributes viz pH, viscosity and Spreadability which was found to be optimum for LF2.

Table 5: *In-vitro* drug release data for Tazarotene Marketed Formulation

Time (min)	Square root of Time(h) ^{1/2}	Log Time	Cumulative* % Drug Release	Log Cumulative* % Drug Release	Cumulative % Drug Remaining	Log Cumulative % Drug Remaining
5	2.236	0.699	33.56±0.12	1.526	66.44±1.58	1.822
10	3.162	1.000	55.45±0.14	1.744	44.55±1.34	1.649
15	3.873	1.176	68.98±0.25	1.839	31.02±1.08	1.492
20	4.472	1.301	88.98±0.21	1.949	11.02±0.04	1.042
25	5.000	1.398	95.45±0.23	1.980	4.55±0.02	0.658
30	5.477	1.477	98.58±0.21	1.995	1.22±0.02	0.086

*Average of three readings

Table 6: *In-vitro* drug release data of optimized batch LF2 for hydroquinone

Time (min)	Square root of Tim(h) ^{1/2}	Log Time	Cumulative* % Drug Release	Log Cumulative* % Drug Release	Cumulative % Drug Remaining	Log Cumulative % Drug Remaining
5	2.236	0.698	22.25±0.45	1.347	77.75	1.890
10	3.162	1	50.45±0.21	1.702	49.55	1.695
15	3.872	1.176	65.54±0.14	1.816	34.46	1.537
20	4.472	1.301	80.12±0.15	1.903	19.88	1.298
25	5	1.397	90.45±0.21	1.956	9.55	0.980
30	5.477	1.477	98.89±0.56	1.995	1.11	0.045

*Average of 03 readings




Fig. 4: *In-vitro* drug release data of optimized batch LF2 for hydroquinone

Table 7: *In-vitro* drug release data optimized batch LF2 for tazarotene

Time (h)	Square root of Time(h) ^{1/2}	Log Time	Cumulative* % Drug Release	Log Cumulative % Drug Release	Cumulative % Drug Remaining	Log Cumulative % Drug Remaining
1	1.000	0.000	23.450±0.15	1.370	76.550	1.884
2	1.414	0.301	35.450±0.14	1.550	64.550	1.810
3	1.732	0.477	50.450±0.25	1.703	49.550	1.695
4	2.000	0.602	63.450±0.14	1.802	36.550	1.563
6	2.449	0.778	75.450±0.15	1.878	24.550	1.390
8	2.828	0.903	84.560±0.36	1.927	15.440	1.189
12	3.464	1.079	98.120±0.45	1.992	1.880	0.274

*Average of 03 readings




Fig. 5: *In-vitro* drug release data optimized batch LF2 for tazarotene

Table 8: Effect of storage temperature on the vesicle size of drug (Tazarotene) loaded liposomal gel LF2

Time (Days)	Average Vesicle Size (nm)	
	4.0 ± 1°C	28 ± 1°C
0	168.3	168.2
7	168.5	175.8
14	168.2	179.4
21	168.2	183.7
28	168.5	187.2

*Average of 03 readings

Table 9: Effect of storage temperature on the % drug content of Tazarotene loaded liposomal gel LF2

Time (Days)	Drug Content (%)	
	4.0 ±1°C	28 ± 1°C
0	99.181 ± 0.020	98.182 ± 0.020
7	98.864± 0.124	98.102 ± 0.123
14	98.426± 0.256	98.012 ± 0.458
21	98.114 ± 0.421	97.014 ± 0.754
28	98.954 ± 0.411	96.425 ± 0.412

*Average of 03 readings

Table 10: Effect of storage temperature on the % drug content of Hydroquinone loaded liposomal gel LF2

Time (Days)	Drug Content (%)	
	4.0 ±1°C	25 ± 1°C
0	99.211± 0.010	98.125± 0.010
7	98.621± 0.0112	98.101± 0.112
14	98.321± 0.143	98.011± 0.323
21	98.012± 0.322	98.012± 0.643
28	98.824± 0.312	97.324± 0.334

*Average of 03 readings

Stability of optimized (1% w/W LF2) liposomal gel containing drugs was carried out for 4 weeks at 4.0 ± 1°C and 25 ± 1°C (room temperature). Responses obtained for different parameters for liposomal gel during stability period. Liposomes were found to be reasonably stable in terms of aggregation, fusion and/or vesicle disruption tendencies, over the studied storage period. From results it can be concluded that at room temperature and freeze temperature there was slight decrease in % entrapment efficiency

which is insignificant and also an increase in vesicle size was observed for the optimized batch at $25 \pm 1^\circ\text{C}$. This is due to the fact that at a higher temperature the vesicles tend to collide with each other due to an increase in the mean kinetic energy and as a result they fuse with each other resulting in the increase in the size. During collision, fusion and reformation of the vesicles there is a slight loss of the drug because of the bilayer disruption and hence a very less or insignificant loss of drug occurs. The result suggests that keeping the liposomal product in refrigeration conditions minimizes stability problems of liposomal gel and hence the best suited temperature for liposomal gel is $4.0 \pm 1^\circ\text{C}$.

Conclusions

Overall results obtained during this work have shown that liposomes could prove an interesting carrier for tazarotene in combination with hydroquinone for topical delivery, when appropriate formulations are used. The effectiveness of the drug would be increased with the liposomal system. Tazarotene in combination with hydroquinone molecules could be successfully entrapped in liposomes with reasonable drug loading. These findings have been seen to support the improved and localized drug action in the skin, thus providing a better option to deal with skin-related problems. Hence from the results obtained it can be concluded that liposomal gel containing tazarotene in combination with hydroquinone has potential application in topical delivery.

References

1. Mozafari MR. Liposomes: An overview of manufacturing techniques. *Cellular and Molecular Biology Letters*. 2005;10(4):711 – 719.
2. Egbaria K and Weiner N. Liposomes as a topical drug delivery system. *Advanced Drug Delivery Reviews*. 1990; 5(3): 287-300.
3. Gulati M, Grover G, Singh S and Singh M. Lipophilic drug derivatives in liposomes. *International Journal of Pharmaceutics*. 1998; 165(2):129-168.
4. Schmid MH and Korting HC. Therapeutic progress with topical liposome drugs for skin disease. *Advanced Drug Delivery Reviews*. 1996; 18(3): 335-342.
5. Lauer AC, Ramchandran C, Linda LM, Niemiec S and Weiner ND. Targeted delivery to the pilosebaceous unit via liposomes. *Advanced Drug Delivery Reviews*. 1996; 18(3), 311-324.
6. Samani SM, Montaseri H and Jamshidnejad M. Preparation and evaluation of cyproterone acetate liposome for topical drug delivery. *Iranian Journal of Pharmaceutical Sciences*. 2009; 5(4), 199-204.

7. Mansoori MA, Jawade S, Agrawal S and Khan MI. Formulation development of ketoprofen liposomal gel. *Journal of Pharmaceutics and Cosmetology*. 2012; 2(10): 22-29.
8. Nagarsenker MS and Joshi AA. Preparation characterization and evaluation of liposomal dispersions of lidocaine. *Drug Development and Industrial Pharmacy*. 1997; 23(12): 1159-1165.
9. Nagarsenker MS, Tantry JS and Shenai H. Influence of hydroxypropylb-cyclodextrin on the dissolution of ketoprofen and irritation to gastric mucosa after oral administration in rats. *Pharmacy and Pharmacology Communication*. 1997; 3(9): 443-445.
10. Jung BH and Chung SJ. Proliposomes as prolonged intranasal drug delivery systems. *STP Pharma Science*. 2002;12(1): 33-38.
11. Katare OP, Vyas SP and Dixit VK. Proliposomes of indomethacin for oral administration. *Journal of Microencapsulation*. 1991;8(1): 1-7.
12. Patel V.B., Misra A.N., Marfatia Y.S., 2001. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. *Drug Development and Industrial Pharmacy*. 27 (8), 864-870.
13. Bhalaria MK, Naik S and Misra AN. Ethosomes: A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. *Indian Journal of Experimental Biology*. 2009;47(5): 368-375.
14. Mallesh K, Bari MA and Diwan PV. Estimation of prednisolone in proliposomal formulation using rp-hplc method. *International Journal of Research in Pharmaceutical Biomedical Sciences*. 2011;2(4): 1663-1669.
15. Chen QI, Huang YU and Gu XQ. A study on preparation of proliposomes by spray drying method. *Journal of Shenyang Pharm Univ*. 1997;1(4): 166-169.